Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA; for NRG Oncology.

J Clin Oncol. 2020 Apr 1;38(10):1019-1029. doi: 10.1200/JCO.19.02767. Epub 2020 Feb 14.

PMID:
32058845
2.

Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis.

Zeng Y, Dong J, Huang M, Zhang JE, Zhang X, Xie M, Wefel JS.

Int J Nurs Stud. 2020 Apr;104:103514. doi: 10.1016/j.ijnurstu.2019.103514. Epub 2020 Jan 3.

PMID:
32004776
3.

ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.

Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim NK.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.3258.2019. doi: 10.1158/1078-0432.CCR-19-3258. [Epub ahead of print]

4.

A review of prostate cancer treatment impact on the CNS and cognitive function.

Ryan C, Wefel JS, Morgans AK.

Prostate Cancer Prostatic Dis. 2019 Dec 16. doi: 10.1038/s41391-019-0195-5. [Epub ahead of print]

PMID:
31844181
5.

Driver safety in patients with primary brain tumors.

Estevis E, Noll KR, Bradshaw ME, Wefel JS.

Neurooncol Pract. 2019 Dec;6(6):490-498. doi: 10.1093/nop/npz014. Epub 2019 Apr 11.

PMID:
31832220
6.

Meta-Analysis of the Efficacy of Virtual Reality-Based Interventions in Cancer-Related Symptom Management.

Zeng Y, Zhang JE, Cheng ASK, Cheng H, Wefel JS.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419871108. doi: 10.1177/1534735419871108.

7.

The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy.

Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D.

Neurooncol Pract. 2019 Jul;6(4):274-282. doi: 10.1093/nop/npy038. Epub 2018 Dec 3.

PMID:
31386073
8.

Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy.

Wefel JS.

Neurooncol Pract. 2019 Jul;6(4):247-248. doi: 10.1093/nop/npz035. Epub 2019 Jul 27. No abstract available.

PMID:
31386055
9.

Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities.

Wefel JS.

Neurooncol Pract. 2018 Nov;5(4):203. doi: 10.1093/nop/npy045. Epub 2018 Nov 2. No abstract available.

10.

Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors.

Noll KR, Bradshaw ME, Parsons MW, Dawson EL, Rexer J, Wefel JS.

Curr Treat Options Neurol. 2019 Jun 28;21(7):33. doi: 10.1007/s11940-019-0573-2. Review.

PMID:
31250277
11.

Interventions for cognitive problems in adults with brain cancer: A narrative review.

van Lonkhuizen PJC, Klaver KM, Wefel JS, Sitskoorn MM, Schagen SB, Gehring K.

Eur J Cancer Care (Engl). 2019 May;28(3):e13088. doi: 10.1111/ecc.13088. Epub 2019 May 14. Review.

PMID:
31090162
12.

Depressive symptoms and executive function in relation to survival in patients with glioblastoma.

Noll KR, Sullaway CM, Wefel JS.

J Neurooncol. 2019 Mar;142(1):183-191. doi: 10.1007/s11060-018-03081-z. Epub 2019 Jan 24.

PMID:
30680509
13.

Neurocognitive dysfunction in adult cerebellar medulloblastoma.

Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS.

Psychooncology. 2019 Jan;28(1):131-138. doi: 10.1002/pon.4920. Epub 2018 Nov 5.

PMID:
30315720
14.

Cognitive Changes in Cancer Survivors.

Hardy SJ, Krull KR, Wefel JS, Janelsins M.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:795-806. doi: 10.1200/EDBK_201179. Review.

15.

Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma.

Noll KR, Bradshaw ME, Weinberg JS, Wefel JS.

Neurooncol Pract. 2018 Aug;5(3):184-193. doi: 10.1093/nop/npx028. Epub 2017 Nov 19.

16.

Neurocognitive Function in Adult Cancer Patients.

Harrison RA, Wefel JS.

Neurol Clin. 2018 Aug;36(3):653-674. doi: 10.1016/j.ncl.2018.04.014. Review.

PMID:
30072075
17.

Neuropsychological Practice in the Oncology Setting.

Noll KR, Bradshaw ME, Rexer J, Wefel JS.

Arch Clin Neuropsychol. 2018 May 1;33(3):344-353. doi: 10.1093/arclin/acx131.

18.

Association of genetic variants with fatigue in patients with malignant glioma.

Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME.

Neurooncol Pract. 2018 May;5(2):122-128. doi: 10.1093/nop/npx020. Epub 2017 Sep 19.

19.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.

Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B.

Neurosurgery. 2019 Jan 1;84(1):66-76. doi: 10.1093/neuros/nyy003.

20.

Patient-centered care in neuro-oncology.

Wefel JS.

Neurooncol Pract. 2018 Mar;5(1):1. doi: 10.1093/nop/npy005. Epub 2018 Mar 2. No abstract available.

21.

Neurocognitive aspects of brain metastasis.

Wefel JS, Parsons MW, Gondi V, Brown PD.

Handb Clin Neurol. 2018;149:155-165. doi: 10.1016/B978-0-12-811161-1.00012-8. Review.

PMID:
29307352
22.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review.

PMID:
29304360
23.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
24.

Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?

Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V.

J Clin Oncol. 2018 Feb 10;36(5):483-491. doi: 10.1200/JCO.2017.75.9589. Epub 2017 Dec 22. Review.

25.

Choosing clinical trial endpoints, aggregating data, and making clinical decisions.

Wefel JS.

Neurooncol Pract. 2017 Dec;4(4):199-200. doi: 10.1093/nop/npx032. Epub 2017 Dec 1. No abstract available.

26.

Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy.

Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS.

Mol Cell Neurosci. 2018 Jan;86:65-71. doi: 10.1016/j.mcn.2017.11.014. Epub 2017 Nov 24.

27.

Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study.

Salek KE, Hassan IS, Kotrotsou A, Abrol S, Faro SH, Mohamed FB, Zinn PO, Wei W, Li N, Kumar AJ, Weinberg JS, Wefel JS, Kesler SR, Liu HA, Hou P, Stafford RJ, Prabhu S, Sawaya R, Colen RR.

Sci Rep. 2017 Sep 21;7(1):12054. doi: 10.1038/s41598-017-11192-2.

28.

Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module.

Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Lewis CM, Kupferman ME, Johnson JM, Skinner HD, Lai SY, Hanna EY, Rosenthal DI, Fuller CD, Gunn GB; MD Anderson Head and Neck Cancer Symptom Working Group.

Head Neck. 2017 Oct;39(10):2048-2056. doi: 10.1002/hed.24876. Epub 2017 Aug 1.

29.

Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All.

Schagen SB, Wefel JS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx091. No abstract available.

PMID:
28521366
30.

Reply to Freyschlag et al.

Wefel JS, Noll KR, Rao G, Cahill DP.

Neuro Oncol. 2017 Apr 1;19(4):598-599. doi: 10.1093/neuonc/now296. No abstract available.

31.

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY.

J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23.

32.

TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin.

Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS.

Aging (Albany NY). 2016 Dec 16;8(12):3507-3519. doi: 10.18632/aging.101144.

33.

Neuro-Oncology Practice: Learning from our past to guide our future.

Wefel JS.

Neurooncol Pract. 2016 Dec;3(4):209-210. doi: 10.1093/nop/npw024. Epub 2016 Nov 1. No abstract available.

34.

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma.

Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS.

J Neurooncol. 2017 Feb;131(3):565-574. doi: 10.1007/s11060-016-2328-1. Epub 2016 Nov 15.

35.

Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.

Wefel JS, Noll KR, Rao G, Cahill DP.

Neuro Oncol. 2016 Dec;18(12):1656-1663. Epub 2016 Aug 30.

36.

Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons.

Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS.

Sci Rep. 2016 May 11;6:25705. doi: 10.1038/srep25705.

37.

Neurocognitive functioning in patients with glioma of the left and right temporal lobes.

Noll KR, Ziu M, Weinberg JS, Wefel JS.

J Neurooncol. 2016 Jun;128(2):323-31. doi: 10.1007/s11060-016-2114-0. Epub 2016 Mar 29.

38.

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS.

Neuro Oncol. 2016 Mar;18 Suppl 2:ii13-ii20. doi: 10.1093/neuonc/nov291. Review.

39.

Neurocognitive functioning and genetic variation in patients with primary brain tumours.

Wefel JS, Noll KR, Scheurer ME.

Lancet Oncol. 2016 Mar;17(3):e97-e108. doi: 10.1016/S1470-2045(15)00380-0. Epub 2016 Mar 2. Review.

40.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

41.

Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma.

Noll KR, Bradshaw ME, Weinberg JS, Wefel JS.

Psychooncology. 2017 May;26(5):617-624. doi: 10.1002/pon.4046. Epub 2015 Dec 17.

42.

Cancer neurology, neuro-oncology, and clinical decision making.

Wefel JS.

Neurooncol Pract. 2015 Dec;2(4):159-160. doi: 10.1093/nop/npv058. Epub 2015 Nov 3. No abstract available.

43.

Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes.

Noll KR, Weinberg JS, Ziu M, Wefel JS.

Arch Clin Neuropsychol. 2016 Feb;31(1):37-46. doi: 10.1093/arclin/acv064. Epub 2015 Nov 3.

44.

Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function".

Noll KR, Wefel JS.

Neuro Oncol. 2015 Oct;17(10):1421-2. doi: 10.1093/neuonc/nov176. No abstract available.

45.

Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012.

Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H.

J Pain Symptom Manage. 2015 Dec;50(6):830-41. doi: 10.1016/j.jpainsymman.2015.06.019. Epub 2015 Sep 5. Review.

46.

Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma.

Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS.

Neurosurgery. 2015 Nov;77(5):777-85. doi: 10.1227/NEU.0000000000000987.

47.

Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions.

Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS.

EJC Suppl. 2014 Jun;12(1):29-40. doi: 10.1016/j.ejcsup.2014.03.003. Epub 2014 May 29.

48.

Neuro-Oncology Practice: Time Flies When You Are Having Fun!

Wefel JS.

Neurooncol Pract. 2014 Dec;1(4):143-144. No abstract available.

49.

Genetic Modulation of Neurocognitive Function in Glioma Patients.

Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS.

Clin Cancer Res. 2015 Jul 15;21(14):3340-6. doi: 10.1158/1078-0432.CCR-15-0168. Epub 2015 Apr 22.

50.

Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Wefel JS, Kesler SR, Noll KR, Schagen SB.

CA Cancer J Clin. 2015 Mar;65(2):123-38. doi: 10.3322/caac.21258. Epub 2014 Dec 5. Review.

Supplemental Content

Loading ...
Support Center